(2025) showed average weight loss of 16.7% at just 1.02 mg/week average semaglutide dose, with 98% achieving at least 5% body weight loss
Endocrinol Metab Clinics North Am
By accepting our use of cookies, your data will be aggregated with all other user data.
NAION Management and Prognosis in GLP-1 Drug Users For high-risk patients using GLP-1 drugs, close monitoring is essential
All this said, remember to consult your healthcare provider if you have any questions about adjusting your tirzepatide dosing schedule
March 3rd, 2026: Federal Judge Appoints Leadership for GLP1 Vision Loss Lawsuits Multiple lawsuits alleging vision loss from GLP1 drugs, including Ozempic, Wegovy, and Mounjaro have been consolidated into a multidistrict litigation in the Eastern District of Pennsylvania, the same court responsible for handling GLP-1 lawsuits involving gastrointestinal injuries